7 top CRISPR stocks to buy in 2024

The best CRISPR stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.

7 Popular CRISPR stocks picks to buy in 2024

We round up a selection of stocks in or related to the gene editing industry, weighting the list more heavily towards popular mid- and large-cap US stocks.

1. Crispr Therapeutics (CRSP)
2. Editas Medicine (EDIT)
3. Regeneron Pharmaceuticals (REGN)
4. Cellectis (CLLS)
5. Beam Therapeutics Inc (BEAM)
6. Bluebird bio (BLUE)
7. Sangamo Therapeutics (SGMO)

Compare premium accounts that help you research stocks

The CRISPR stocks industry is affected by a range of complex factors such as trade policies, regulations, and fluctuating supply and demand. So when considering CRISPR stocks to buy, it's important that you have access to vital information about a company's financial health, leadership team, and market positioning.

Our picks for platforms with research tools

How to invest in CRISPR stocks

1. Choose an online stock trading platform. Choose from our Top Picks above, use our comparison table below or jump straight to the best stock trading apps of 2024.
2. Sign up for an account. Provide your personal information and sign up.
3. Set up a funding method to pay for the transaction. Deposit funds into your account by linking your banking information.
4. Choose the stocks you want to buy. Search for the stock by name or ticker symbol like CRSP or EDIT.
5. Place your order. Buy the stock. It's that simple.

Take a deeper dive into CRISPR stocks

If you're interested in investing in the gene editing industry, take a closer look at what companies in this industry do and how the stocks have historically performed. Keep in mind that positive past performance doesn't guarantee that a stock will continue to rise in the future.

---

1. Crispr Therapeutics (CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.

Crispr Therapeutics stock opened the day at $52.11 after a previous close of $53.29. The latest price was $53.55 (25-minute delay). Crispr Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD271.7 million and employs 407 staff.

• Market capitalization: $4,435,142,144
• PEG ratio: -0.2142

Back to top

---

2. Editas Medicine (EDIT)

Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology.

Editas Medicine stock opened the day at $5.19 after a previous close of $5.04. The latest price was $5.56 (25-minute delay). Editas Medicine is listed on the NASDAQ, has a trailing 12-month revenue of around USD$78.1 million and employs 265 staff.

• Market capitalization: $435,021,568
• PEG ratio: 0

Back to top

---

3. Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Regeneron Pharmaceuticals stock opened the day at $959.59 after a previous close of $955.76. The latest price was $968.00 (25-minute delay). Regeneron Pharmaceuticals is listed on the NASDAQ, has a trailing 12-month revenue of around USD$13.1 billion and employs 13,677 staff.

• Market capitalization: $105,311,371,264
• P/E ratio: 28.2518
• PEG ratio: 1.4591

Back to top

---

4. Cellectis (CLLS)

Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

Cellectis stock opened the day at $3.01 after a previous close of $3.10. The latest price was $3.24 (25-minute delay). Cellectis is listed on the NASDAQ and has a trailing 12-month revenue of around USD$9.2 million.

• Market capitalization: $215,140,976
• PEG ratio: 0

Back to top

---

5. Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc. , a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

Beam Therapeutics Inc stock opened the day at $22.24 after a previous close of $22.24. The latest price was $22.54 (25-minute delay). Beam Therapeutics Inc is listed on the NASDAQ, has a trailing 12-month revenue of around USD$377.7 million and employs 436 staff.

• Market capitalization: $1,903,834,880

Back to top

---

6. Bluebird bio (BLUE)

bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

Bluebird bio stock opened the day at $1.02 after a previous close of $0.97. The latest price was $1.12 (25-minute delay). Bluebird bio is listed on the NASDAQ, has a trailing 12-month revenue of around USD$21.7 million and employs 323 staff.

• Market capitalization: $173,429,248
• PEG ratio: 0.32

Back to top

---

7. Sangamo Therapeutics (SGMO)

Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Sangamo Therapeutics stock opened the day at $0.50 after a previous close of $0.50. The latest price was $0.52 (25-minute delay). Sangamo Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$176.2 million and employs 405 staff.

• Market capitalization: $115,326,280
• PEG ratio: 0

Back to top

Compare more stock trading platforms to invest in CRISPR stocks

Compare online trading platforms by fees, asset types and bonuses to find the best for your investment in CRISPR stocks.

Bottom line

While it’s possible to turn a profit investing in CRISPR stocks, keep in mind that — like any investment — CRISPR stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the gene editing industry, so carefully vet your picks before you invest. And if you’re new to investing, or if it’s been awhile since you’ve taken a critical look at your investing accounts, compare brokers to make sure you’re getting the best features in your trading account.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.